Alvotech signs u.s. agreement to expand access for newly approved high-concentration interchangeable biosimilar to humira® (adalimumab)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to adalimumab-ryvk in the u.s. market, the newly u.s. food and drug administration (fda) approved high-concentration interchangeable biosimilar to humira.
ALVO Ratings Summary
ALVO Quant Ranking